Browse Articles
Discover research articles across all indexed journals
Hypoxia-activated oxidative stress mediates SHP2/PI3K signaling pathway to promote hepatocellular carcinoma growth and metastasis
Contemporary post-prostatectomy radiation therapy for prostate cancer within a statewide quality consortium.
369 Background: The 2024 AUA Salvage Therapy for Prostate Cancer Guideline provides guidance at the time of suspected recurrence after radical prostatectomy (RP). Recommendations include early initiation of post-operative radiation therapy (RT), and the addition of androgen deprivation therapy (ADT) for those with high-risk features. Given that an increasing number of men receive RP for high-risk disease, we characterized RT in a prospective cohort from the Michigan Radiation Oncology Quality Consortium (MROQC) and the Michigan Urological Surgery Improvement Collaborative (MUSIC). Methods: Patients who received post-RP RT at an MROQC center from 06/09/20 – 09/18/24 were eligible. The MUSIC database provided surgical pathology variables, and MROQC prospectively collected data via patient-, physician-, and physicist-completed forms. RT was defined as adjuvant (pre-RT PSA <0.1 ng/mL), consolidative (persistently elevated PSA post-RP), or salvage. Multivariable analyses (MVA) were used to evaluate associations between ADT intent and patient and clinical features, including high risk features (pT3b/T4, pN1, grade group (GG) 4/5, pre-RT PSA >0.5 ng/mL, consolidative). Results: A total of345 patients at 26 centers received RT. The median pre-RT PSA was 0.3 ng/mL (IQR: 0.2-0.6); PET staging was done in 60%, and 34% had genomics testing. RT was adjuvant in 10% (n = 35), consolidative in 28% (n = 95), and salvage in 62% (n = 215). Median pre-RT PSA in each subgroup was 0.07 (IQR: 0.03-0.09), 0.5 (IQR: 0.3-1.5), and 0.3 (IQR: 0.2-0.5) ng/mL, respectively (p=0.005). Median time to RT post-RP was 8, 6, and 29 months, respectively. Most patients (62%) had at least one high risk feature including pT3b (24%), pN1 (5%), GG 4/5 (30%), Pre-RT PSA >0.5 ng/mL (27%), and PSA persistence (28%). Consolidative patients had worse pathologic features compared to salvage patients: pT3b (35% vs. 15%), pN1 (9.5% vs. 0.5%), GG 4/5 (42% vs. 24%), and pre-RT PSA (0.5 vs. 0.3 ng/mL), p<0.01 for all. Sixty percent (n = 204) were prescribed ADT, with an intended duration of ≤6 months in 133 men (65%) and ≥24 months in 34 (17%). On MVA, ADT use was positively associated with high-risk features including pN1 (OR 6.22 [95% CI 1.35 – 47.57]), pT3b/T4 (ref. pT2, OR 2.77 [95% CI 1.34 – 5.93]), GG 4/5 (ref. GG 1/2, OR 2.87 [95% CI 1.51 – 5.56]), pre-RT PSA ≥0.5 ng/mL (OR 2.11 (95% CI 1.17 – 3.91]). ADT was less often used with adjuvant RT (ref. salvage, OR 0.17 [95% CI 0.06 – 0.45]). Conclusions: In a contemporary statewide quality consortium, salvage RT was delivered at a PSA ≤0.5 in nearly 75% of patients, and ADT use was associated with high-risk features. Importantly, 62% of patients have at least one high-risk feature, and over 25% received consolidative RT for persistently positive PSA. Optimized treatment strategies are needed for this at-risk population that has been underrepresented on many modern trials.
Non-clear cell renal cell carcinoma in the immune checkpoint era: A retrospective study on survival and treatment approaches.
512 Background: Non-clear cell renal cell carcinoma (nccRCC) includes several molecularly distinct subtypes of renal carcinoma. Due to their rarity, nccRCC subtypes have been understudied, and treatment options are often adapted from clear cell RCC therapies. Trials investigating immune checkpoint inhibitors (ICIs) have demonstrated promising efficacy and survival benefits in certain nccRCC histologies. This report aims to present our experience with nccRCC, focusing on patient characteristics, treatment choices, and survival outcomes in the era of ICIs. Methods: A retrospective analysis was conducted on adult patients with metastatic RCC treated at the Emory Winship Cancer Institute between 2018 and 2024. nccRCC histologies were identified and confirmed through pathology reports. An objective response is defined as a complete or partial response by RECIST v1.1. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method with SAS 9.4 software to calculate survival probabilities. Results: We identified 69 patients with various nccRCC histologies, with papillary RCC (pRCC) being the most common (36.2%), followed by unclassified RCC (24.6%). The median age was 63 years. 59.4 of the patients were male, and 75.4% of the patients had an ECOG PS of 0 or 1. 53.6% of the patients were White, while 40.6% were African American or Black. Nephrectomy was performed in 44 patients (63.8%). The median follow-up time was 24 months. ICI-based treatments were used as the first-line option in 52% of patients, with 88% of unclassified RCC patients receiving ICI-based regimens as first-line. The mOS was longest in patients with chromophobe RCC at 21 months (4, NA), followed by patients with unclassified RCC at 19 months (6, NA). Among pRCC patients, there was no significant difference in mOS between African American or Black patients (12 months) and White patients (10.5 months; p=0.61). mOS was similar across ICI monotherapy, dual ICI therapy, and ICI+TKI combinations. 12-month survival rates were 50%, 57%, and 33% (p=0.21), and objective response rates (ORR) were 11%, 14%, and 11% for ICI monotherapy, dual ICI, and ICI+TKI combinations, respectively. Conclusions: Our study highlights the heterogeneity of non-clear cell RCC subtypes. The rare nature of nccRCC and the small patient cohort in our study limited its statistical power, emphasizing the importance of larger studies and expanded clinical trials to better understand and optimize treatment strategies for this understudied group of renal carcinomas. Histology n White African American or Black 12 Months OS Rate 12 Months PFS Rate ORR Papillary 25 12 12 46% (25, 64) 44% (7, 78) 12% Unclassified 17 10 6 63% (35, 81) 43% (10, 73) 35% Translocation 9 4 3 67% (21, 91) 36% (17, 56) 0% Collecting Duct 7 4 3 43% (10, 73) 0% (NA) 14% Chromophobe 6 6 - 67% (20, 90) 34% (12, 58) 0%
Socioeconomic position as a social determinant of health and its effect on cardiovascular outcomes and mortality in patients with prostate cancer: A SEER-Medicare based study.
315 Background: Socioeconomic position (SEP) is a key social determinant of health (SDOH) associated with disparities in cancer care and cardiovascular (CV) outcomes in patients with prostate cancer (PC). Understanding the impact of SEP on cardiovascular health is critical for addressing inequities in PC CV outcomes. Methods: We conducted a retrospective cohort study on the SEER-Medicare database. Multiple CV outcomes were assessed in patients ≥65 years of age with no prior CV disease and with localized or advanced PC. SEP was defined using the census-tract level Yost index where those living in first and second quintiles were considered as living in low SEP areas. A competing risk analysis using univariable and multivariable Fine-Gray Models was used for CV events (CVE), CV mortality (CVm) and PC specific mortality (PCsm). CVEs included myocardial infarction, heart failure, atrial fibrillation, ischemic stroke, and peripheral artery disease. All-cause mortality was assessed using Cox proportional hazard (PH) models. All models were adjusted for age, race, marital status, education level, PC grade, PC TNM stage, diabetes, hypertension, hyperlipidemia, chronic kidney disease, and receiving chemotherapy. A sub-group analysis was further conducted in patients who self-identified as non-Hispanic Black (NHB). Results: We included 150,647 patients of whom 102,271 had high SEP and 48,376 had low SEP. Patients with low SEP have shown higher associated risks of CVm (subdistribution hazard ratio [sHR] 1.25, 95% CI 1.19-1.32, p<0.001), PCsm (sHR: 1.20, 95% CI 1.14-1.26, p<0.001), CVE (sHR 1.07, 95% CI 1.04-1.09, p<0.001), and all-cause mortality (adjusted HR 1.17, 95% CI 1.14-1.20, p<0.001) when compared to patients with high SEP. Similarly, in the NHB subgroup analysis, patients with low SEP showed an increase of 11% in CVE, 37% in CVm, and 21% in PCsm and 20% all-cause mortality (Table). Conclusions: Adverse SEP, as a proxy for SDOH, plays an important role in patients with localized or metastatic PC by increasing associated risks for adverse cardiovascular and survival outcomes by up to 25% in the overall population and 37% in NHB individuals. Survival analysis using Fine-Gray analysis (competing risk models) and Cox PH regression for the various cardiovascular outcomes using the fully adjusted model. Overall (n=150,647) NHB (n=15,474) CVE (Competing risk = All-cause mortality)sHR (95% CI, p-value) 1.07 (1.04-1.09, p<0.001) 1.11 (1.03-1.20, p=0.007) CVm (Competing risk = All-cause mortality except CVD mortality)sHR (95% CI, p-value) 1.25 (1.19-1.32, p<0.001) 1.37 (1.15-1.64, p<0.001) PCsm (Competing risk = All-cause mortality except PCsm)sHR (95% CI, p-value) 1.20 (1.14-1.26, p<0.001) 1.21 (1.04-1.41, p=0.016) All-cause mortality (Cox)aHR (95% CI, p-value) 1.17 (1.14-1.20, p<0.001) 1.20 (1.08-1.35, p=0.001)
The impact of climate variability on agricultural employment in Mexico from 1980–2017
Employment in the agricultural sector is highly dependent on climate. Most agricultural jobs worldwide rely on predictable precipitation, in terms of both quantity and seasonality. Mexico is a largely agrarian country, with at least 20 million people directly reliant on food production for the livelihoods. However, research on the relationship between climate variability and agrarian employment is limited in the nation, complicating the development of effective adaptation strategies to drought and climate change. This study aims to address this gap, by analyzing the employment changes of farmers and livestock producers at a national level in the past five decades (1980 to 2017) and its relationship to long-term precipitation variability. We employed governmental datasets from national agrarian surveys and national precipitation, both at the annual scale and seasonally within each year. We found a negative relationship between agricultural employment and total annual precipitation. In particular, employment in the livestock sector showed a negative correlation with current-year precipitation (p = 0.06, cor = -0.33), while employment in rainfed agriculture was linked to the previous year’s rainfall (p = 0.07, cor = -0.33). It is likely that this pattern was driven by the positive relationship of precipitation with planted cropland area (p<0.05, cor = 0.19) and agrarian income (p<0.05, cor = 0.18). We also found that as many as 10 million people left the agrarian employments each year during the dry season. Finally, as precipitation continues to pose a challenge, it may have contributed to people of ages 23 to 35 to leave in recent years, compared to 15 and 19 in the 1990s. These findings underscore the need for national policies to mitigate the impacts of dry years on livelihoods and to inform strategies for building resilience in the agricultural sector.
Tester selection for combining ability estimation of storage root yield and sweetpotato virus disease in sweetpotato breeding
Abstract General combining ability (GCA) is the major selection criterion for new sweetpotato (Ipomoea batatas) parents in a reciprocal recurrent selection (RRS) scheme. Here we aimed to estimate GCA and specific combining ability (SCA) by using 16 potential testers involved in an 8 × 8 partial diallel and propose a procedure to identify testers in sweetpotato breeding. Data on storage root yield in tons per hectare (rytha), and sweetpotato virus disease (vir2) from 64 families (1,913 clones) were collected in five trials at two locations in Uganda. The estimates of the female GCA accounted for the largest additive genetic variation for storage root yield compared to the male GCA for both traits. Mid-parent heterosis ranged from − 6.2 to 7% for rytha, and − 1.1 to 1.3% for vir2 in the progeny families. A stepwise procedure to identify testers top-ranked ‘NASPOT 7’ as a dual tester for both traits. Besides this parent, ‘Ejumula’ and ‘NASPOT 10 O’ for rytha, and ‘NASPOT 1’, ‘NK259L’, ‘SPK004’, and ‘NASPOT 11’ for vir2 are particularly suitable as respective single-trait testers. Testers are important in many plant breeding programs to enhance efficiency of RRS, and thus other crop species might benefit from the strategy and methods applied herein.
Expression of tissue factor (TF) in penile squamous cell carcinoma (PSCC) and enrichment in HPV-negative cases.
10 Background: Advanced/metastatic PSCC is an aggressive malignancy with limited treatment options. An antibody-drug conjugate (ADC) targeting TF is approved for treatment of advanced cervical cancer and may benefit patients with PSCC. We evaluated TF expression in PSCC which could support a future clinical trial of a TF-targeting agent for PSCC. Methods: We identified 33 pts with PSCC who underwent primary surgery at MD Anderson from 1999-2017 and had archived primary tumor tissue available for analysis. HPV-positive status was determined by either PCR testing or high-risk HPV in situ hybridization assay. A tissue microarray (TMA) was constructed with 3 cores per tumor. Anti-TF-1 antibody staining was performed by immunohistochemistry and mean H-scores for membrane and cytoplasm staining were assessed (range 0-300) for each tumor. Median H-scores were described and compared between HPV-positive and negative tumors. Percentage of pts with tumors staining positive for TF (≥10% of tumor cells with at least 1+ intensity in cytoplasm and/or membrane) was determined. Association of TF expression with tumor grade, presence of metastatic disease, lymphovascular invasion (LVI), perineural invasion (PNI), recurrence free survival (RFS), and overall survival (OS) was assessed. Results: 17 pts (51.5%) had HPV-positive disease; 19 pts (57.6%) had metastatic disease. 27 tumors (81.8%) stained positive for tissue factor. Median overall membrane TF H-score was 47 (range 1-232). HPV-negative tumors had significantly higher membrane expression of TF (median H-score 70, range 1-232) than HPV-positive tumors (median H-score 19, range 1-123; p=0.004). While analyses were limited by small sample size, we did not find a significant association of TF H-score with tumor grade, presence of metastatic disease, LVI, PNI, RFS, or OS. Conclusions: TF expression was highly prevalent in this PSCC pt cohort. HPV-negative tumors had significantly higher TF expression than HPV-positive tumors; this finding requires further study. These data support further investigation of TF-targeted therapy, such as an ADC, for treatment of PSCC. Variable Overall population HPV-positive(17 patients) HPV-negative(16 patients) Median (range) H-score Membrane 47 (1-232) 19 (1-123) 70 (1-232) Cytoplasm 29 (2-180) 18 (2-98) 59 (2-180) Positive TF expression (Percent of patients with ≥1 core having ≥10% of tumor cells with at least 1+ intensity in either cytoplasm or membrane) 27/33 (81.8%) 12/17 (70.6%) 15/16 (93.8%)
Results of AFU-GETUG-20: A randomised phase 3 trial of adjuvant androgen deprivation therapy with leuprorelin acetate after radical prostatectomy in patients with high-risk localized prostate cancer.
386 Background: After radical prostatectomy (RP), men with an undetectable PSA and specific features (extracapsular extension, seminal vesicle involvement, high Gleason score) are at risk of recurrence. No randomized prospective study has been published with LH-RH agonists in the PSA era. AFU-GETUG-20 is a phase III randomised, open, multicenter trial, designed to evaluate the benefit of adjuvant ADT with leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence. Methods: Patients with high-risk features (postoperative Gleason score > 7, or ≥ 7 with presence of high-grade Gleason patterns, or pT3b), R0, N0 or Nx, M0, and postoperative PSA < 0.1 ng/mL after RP were eligible. Patients were randomized 1:1 to leuprorelin acetate for 24 months vs observation. The primary endpoint was metastases-free survival (MFS). Secondary endpoints included overall survival, disease-specific survival, PSA recurrence-free survival, and quality of life. Originally 700 patients (350 in each arm) and 250 events were required to detect an improvement of MFS with a HR of 0.80 with a bilateral Logrank test with α= 0.05 and β= 0.20. An interim analysis was planned to test the null hypotheses at the 125th event (50% of events) but was eventually held given the low accrual rate and the accrual was stopped after 325 patients had been accrued. Results: Of 325 patients enrolled, 322 are included in the ITT population. 160 were randomized to the Leuprorelin arm and 162 to the observation arm. The median age was 64.7 years [range, 46-77 years]. The median follow-up is 96.1 months [93.6-106.1] IC95% in the leuprorelin arm and 97.2 months [91.8-101.4] IC95% in the surveillance arm. There was no statistically significant difference between arms for MFS (HR = 0.63 [0.30-1.30] 95%CI; p-= 0.204). Similar results were found for PSA relapse-free survival (HR = 0.74 [0.47-1.16]; p = 0 .187), overall survival (HR = 1.24 [0.56-2.76; p = 0.596), and specific survival (HR = 0.57 [0.10-3.17]; p = 0.512). Patients in the leuprorelin arm reported poorer HRQoD on EORTC QLQ-C30 global health scales, social function scale, and specific symptoms (fatigue, pain, dyspnoea, and insomnia). Post-hoc contrast analysis showed a difference between the groups during the treatment period. The two groups returned to comparable levels during follow-up (M36 and M48). Conclusions: Using 2 years of ADT after RP in high-risk patients with an undetectable post-operative PSA did not significantly improve MFS in AFU-GETUG-20. That the trial only accrued about half of the planned patients is the main limitation. The limited number of observed metastatic events in this population, although with a long follow-up, emphasizes the need to identify better biomarkers predicting for relapse to select candidate patients for the next generation of trials. Clinical trial information: EudraCT #:2010-022037-29 UC-0160/1003.
Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy.
704 Background: Muscle-invasive bladder cancer (MIBC) has traditionally been managed with radical cystectomy (RC) and pelvic lymph node dissection combined with neoadjuvant (NAD) and/or adjuvant (AD) chemotherapy in eligible patients. In late 2021, adjuvant nivolumab, was approved in the US among patients with certain high-risk of recurrence (HRR) features. Contemporary peri-operative treatment utilization patterns in MIBC patients post-RC is lacking. This study aimed to characterize demographics, clinical features, treatment patterns, and surgical outcomes, in a contemporary cohort of MIBC patients undergoing RC in the post-immunotherapy era. Methods: The US Syapse Learning Health Network Enriched Bladder Cancer Cohort, comprised of patients from community-based practices with cancer registry data supplemented and validated by chart review, was used to identify adults with clinically diagnosed MIBC (T2-T4aN0M0, T1-T4aN1M0) undergoing RC from February 19, 2021 (6-months prior to nivolumab approval) to December 31, 2023, with a minimum 6-month follow-up post-RC (except in cases of patient death). Patients with history of other primary cancer, non-bladder systemic antineoplastic therapies, prior partial cystectomy, NAD radiation, or clinical trial participation were excluded. Real-world HRR following resection was defined using a combination of NAD agent receipt and pathological staging (PS) from RC: received NAD cisplatin-based therapy and pT2-T4a or pN+; or, if patient did not receive NAD cisplatin-based therapy, pT3-4a or pN+. Pathological complete response (pCR) was defined as pT0N0. Results: Of 138 eligible patients, mean age was 66 years, and the majority were male (82%), white (83%), current/former smokers (68%), presented as de novo MIBC (97%), and had urothelial histology (91%). Overall, 49% (67/138) of patients received RC without NAD or AD treatment. Around 46% (64/138) received NAD chemotherapy; of these, one-third achieved pCR (20/61 NAD chemotherapy-treated patients with complete PS data post-RC). The most prevalent NAD regimens were cisplatin + gemcitabine (58%; 37/64) and methotrexate + vinblastine + doxorubicin + cisplatin (30%; 19/64). Only 14% (20/138) of all patients received AD treatment, with 10% (14/138) receiving AD nivolumab. Half of patients had HRR following resection (63/125 patients with complete PS data post-RC). Among the HRR subgroup, 22% (14/63) received AD treatment, with 19% (12/63) receiving nivolumab. Conclusions: In this contemporary cohort of MIBC patients undergoing RC, nearly half received NAD treatment (mainly gemcitabine and cisplatin) while there was limited use of AD treatment. Since FDA approval, AD nivolumab use was 10% among all RC-treated MIBC patients and less than a fifth among HRR patients (nivolumab eligible).
Evaluation of a home-based parenting support programme—Parenting Young Children—For parents with intellectual and developmental disabilities when there is a risk for neglect: Study protocol for a multi-centre study
Introduction Parents with intellectual and developmental disabilities (IDDs) often need parenting support, but there are few evidence-based programmes adapted to their cognitive needs. Parenting Young Children (PYC), a home-based programme for parents with IDDs, is perceived as beneficial by parents and practitioners, but it is unclear if PYC improves parenting. The purpose of the proposed mixed-methods study is therefore to evaluate the PYC programme for improved parenting in parents with IDDs. Methods and analysis The quantitative evaluation will have a multi-centre, pretest-posttest study design and include parents with IDDs (children aged 0–9) in need of adapted parenting support. Goal-attainment in parenting skills, parental self-efficacy and child mental health will be measured outcomes. Interviews will be used to explore the perspectives of parents and children on PYC. Ethics and dissemination Particpation is based on informed consent from parents and guardians of the participating children. Ethical approval was granted by the Swedish Ethical Review Authority.
Evaluating flood dynamics and effects in Nagpur city using remote sensing and Shannon’s entropy analysis
Abstract Flood is among the most disastrous natural disasters since they are responsible for massive damage to infrastructure, severe fatalities and injuries, innumerable economic losses, and social disruptions worldwide. These damages caused by floods have been worsening in recent years worldwide because of environmental degradation, climatic change, and high-speed urbanization. A rising precipitation rate increases the chances of floods in flood-vulnerable areas. A flash flood is a rapid flooding of geomorphic low-lying regions caused by remarkably high rainfall in a short duration. On September 23rd, 2023 a flooding event in the Nagpur, Maharashtra, it is directly impact on the human death and economic loss entire city. In the present study, the change in the dynamics of Nagpur city was analysed by employing remote sensing and GIS techniques to assess the change in the land use and land cover patterns. Landsat imagery of year 2000, 2010, 2020, and 2023 was used for land use and land cover classification. This analysis reveals that there is an increase in built-up area from 72.85 sq. km in year 2000 to 185.4 sq. km in year 2023. The built up land is increased this changes where directly affects the infiltration rate of rainwater into the soil. The total area covered by water bodies is reduced to 2.29 sq. km in 2023 which were 12.2 sq. km in year 2000. It is indicates the encroachment of built-up land on the water bodies. On the day of flash flood occurrence, it was observed that Nagpur city received 145 mm rainfall which is highest in the month of September, 2023. The Shannon entropy model was used to estimate the population dynamics and growth patterns of Nagpur city. Higher entropy values were obtained during the analysis which indicates the rapid transformation of city in all directions. Population dynamics of Nagpur city also indicate the inflation in population from 4,067,637 in 2000 to 4,653,570 in 2010. The SAR water index was calculated using Google Earth Engine to detect the water surges in residential areas during the flood. Precautionary measures should be taken by governing authorities to avoid such disasters. Proper city planning and improvements in drainage systems are recommended within the city. It is needed for an hour to develop a river monitoring system and early warning system, as well as preventive measures that should be implemented, like the construction of retaining walls to control the flood water.
Effectiveness and safety of first-line atezolizumab in locally advanced or metastatic urothelial cancer: The IMFLAME study.
720 Background: Urothelial cancer (UC) is the tenth most common cancer globally. Standard first-line treatment for metastatic UC (mUC) involves enfotumab-vedotin + pembrolizumab or platinum-based chemotherapies, but some patients are ineligible to standard treatment due to significant comorbidities and poor performance status. Atezolizumab, an immune checkpoint inhibitor, has shown activity in clinical trials. This study evaluates the real-world effectiveness and safety of atezolizumab as a first-line treatment in patients with locally advanced or metastatic UC ineligible for platinum-based chemotherapies. Methods: This retrospective, multicenter, observational study included 91 patients with locally advanced or mUC treated with atezolizumab monotherapy as first-line treatment in Spain. Data were extracted from medical charts, including patient demographics, clinical characteristics, treatment patterns, and outcomes. The primary endpoint was the 12-month survival rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), and safety profile. Results: The median age at diagnosis of mUC was 77 years, and 90.1% of patients had mUC. The population had a high burden of comorbidities, 90,1% had at least 1 comorbidity, 30% of the patients had PS ECOG ≥ 2 and 42.9% had visceral metastases. The 12-month survival rate was 41.8%, decreasing to 30.8% and 19.8% at 18 and 24 months, respectively. The ORR was 45.2%, with a median DoR of 19 months (95% CI: 9.8-28.3). The median PFS was 4.1 months, and the median OS was 9.7 months. According to multivariate COX regression analysis, PS ECOG ≥ 2 was an independent prognostic factor for worse survival. Safety analysis revealed that 26.4% of patients required treatment interruption due to treatment related adverse events (TRAEs), with immune-related adverse events (irAEs) occurring in 12.1% of patients, only 6% of patients discontinued treatment due to an irAEs. Conclusions: First-line atezolizumab monotherapy provides a clinically relevant benefit in terms of response, PFS, and OS in patients with locally advanced or metastatic UC ineligible for platinum-based chemotherapies. Despite the high burden of comorbidities and poor prognosis in this population, atezolizumab demonstrated an acceptable safety profile. These findings support the use of atezolizumab in platinum-ineligible patients and potentially in those who are not suitable for EV-Pembrolizumab under routine clinical practice conditions and highlight the need for further research to optimize patient selection and management. Outcome Measure Value 95% CI 12-month survival rate (%) 41.8 33.5-55.3 18-month survival rate (%) 30.8 23.4-44.5 24-month survival rate (%) 19.8 13.6-32.5 Overall Response Rate (%) 45.2 Median PFS (months) 4.1 Median OS (months) 9.7
Survival in advanced prostate cancer (PCa) patients with visceral metastasis: A population-based SEER study.
134 Background: Prostate cancer patients with visceral metastases at diagnosis are often treated using one-size-fits-all approach. For example, CHAARTED criteria treats any visceral metastasis as high volume. Therefore, we aimed to assess overall survival (OS) by site of visceral involvement in patients with metastatic PCa. Methods: Surveillance, Epidemiology, and End Results (SEER) database (2010-2021) was queried to obtain case listing data on metastatic PCa patients from 17 registries. The patients were categorized into three groups based on visceral metastasis at diagnosis: lung metastasis, liver metastasis, and others. Kaplan-Meier survival analysis was performed to estimate median OS with 95% confidence interval (CI). Log-rank test was conducted to assess if survival was significantly different among the groups. Cox proportional hazard regression analysis was performed to assess the magnitude of difference among the groups. P-value <0.05 established statistical significance. Results: This analysis included 21,007 metastatic PCa patients (lung: n=319; liver: n=123; brain: 107; bone: 20538). Metastatic PCa population with lung metastasis exhibited a median OS of 60 months (95% CI: 48-72) compared to 24 months (95% CI: 12-36) in population with liver metastases and to 36 months (95% CI: 36-36) in population with other metastases. The difference in OS among the groups was statistically significant (p < 0.001). Compared to population with lung metastasis, those with liver (HR: 1.91; 95% CI: 1.41-2.57) but not those with other metastases (1.16; 0.97-1.39) had significantly worse OS adjusting for Gleason score, PSA and race (Table). Conclusions: In metastatic PCa, patients with lung-only metastasis have significantly better overall survival and should be considered differently in prognostication to liver metastases. Consideration of site of visceral metastasis is critical for treatment intensification decisions. Limitations of this analysis include lack of accounting for confounding relationships at individual patient level. Variable Hazard Ratio (95% CI) Metastases (Lung) REFERENCE Metastases (Liver) 1.91 (1.41-2.57) Metastases (Other) 1.16 (0.97-1.39) Gleason score≥8 REFERENCE Gleason score <8 0.68 (0.64 -0.72) PSA - ng/dL 1.01 (1.00 – 1.01) Race (White) REFERENCE Race (Black) 0.99 (0.94 – 1.05) Race (Asian or Pacific Islander) 0.70 (0.64 – 0.76)
Predictive value of neoadjuvant therapy combined with VI-RADS re-scoring in bladder preservation for muscle-invasive bladder cancer.
688 Background: Radical cystectomy (RC) is standard treatment for muscle-invasive bladder cancer (MIBC). However, many patients are unwilling or unable to undergo. Therefore, trimodality treatment (TMT) containing TURBT and chemoradiotherapy is an option for MIBC. However, TMT may not fully assess the effectiveness of maximal tumor resection, which is considered an important factor affecting outcomes. Additionally, neoadjuvant chemotherapy is thought to have limited effectiveness in TMT. The study aims to assess the predictive value of mpMRI VI-RADS’s re-scoring following neoadjuvant therapy in TMT. Methods: The study prospectively selected MIBC patients from January 2021 to August 2023. Inclusion criteria: 1) pathologically confirmed muscle-invasive urothelial carcinoma; 2) age <80 years tolerable cisplatin-based chemotherapy; 3) tumor size unrestricted; 4) initial VI-RADS score of 4-5; 5) no metastasis tested by CT or MRI. Exclusion criteria: 1) anterior urethra invasion; 2) dysfunction bladder; 3) lymph node and/or distant metastasis; 4) postoperative hydronephrosis not improved; 5) absolute contraindications to chemoradiotherapy. Patients underwent maximal TURBT before or after neoadjuvant therapy with gemcitabine plus cisplatin (GC) +/- toripalimab (PD-1) or RC48 plus PD-1, following VI-RADS re-scoring, then approached concurrent bladder radiotherapy (50-64Gy) with low-dose paclitaxel (50 mg/m2, D1/week) plus cisplatin (20 mg/m2, D1-2/week). Bladder recurrence and metastasis were assessed, with follow-up until August 2024 or death. Results: The study included 14 males (82.4%) and 3 females (17.6%); median age 65 (44–76) years, median follow-up 19 (8–40) months. 12 cases were cT2N0 (70.6%), 5 cases were cT3N0 (29.4%). NAC more than 2 cycles were 11 cases (64.6%), combined with PD-1 were 3 cases (17.7%), and RC48 plus PD-1 in 4 cycles were 3 cases (17.7%). Second TURBT after above neoadjuvant therapy were 11 cases (64.6%), whose VI-RADS re-scoring were all 0 points but 3 cases with residue after (3/11, 27.3%). Neoadjuvant therapy following maximal TURBT were 6 cases (35.4%), whose re-scoring was 5 points in 2 cases (11.8%), both cPR and pathological T2; re-scoring of 4 points were 2 cases (11.8%), 2 points and 1 point was respective 1 case (5.9%), who were all cPR and pathological downstaging to T1. 3 cases recurred: 2 cases whose re-scoring were 5 points recurred at the 20 and 31 months and had salvage RC (11.8%, 2/17) ; 1 case recurred at 10 months with T1 stage (1/17), whose re-scoring was 0 points, suffering reTURBT. The 1-year disease-free survival rate for all patients was 94.1% (16/17), no metastasis and death case. Conclusions: The VI-RADS re-scoring after neoadjuvant therapy for MIBC has concordance with postoperative pathology, offer a predictive value for achieving maximal tumor resection, and provide clinical reference for bladder preservation. Clinical trial information: 2000029504.
Use of urinary cell-free DNA fragmentomics in urothelial carcinoma diagnosis.
846 Background: Traditional diagnostic procedures for urothelial carcinoma (UC) are often limited by patient burden and reduced sensitivity, impacting diagnostic accuracy. Liquid biopsy-based molecular detection, particularly through fragmentomics analysis, offers a promising supplement to clinical applications. Fragmentomics, which examines the unique fragmentation patterns of tumor DNA, can provide crucial insights into tumor origin and behavior. This study aims to leverage urinary cell-free DNA (ucfDNA) fragmentomics patterns to enhance the diagnostic capabilities for urothelial carcinoma. Methods: We conducted a case-control study to investigate cfDNA fragment size distributions in urine samples. The study included patients diagnosed with malignant UC (cases) and individuals with benign conditions (controls). High-throughput sequencing was used to identify distinct fragmentomics patterns, including variations in fragment size, end motifs, and genomic coverage at transcription factor binding sites. Diagnostic performance was evaluated using sensitivity, precision, and the area under the curve (AUC). Results: UC patients exhibited distinct fragmentation patterns, characterized by a shift towards shorter cfDNA fragments compared to controls. Analysis of fragment size and genomic coverage provided additional diagnostic insights when combined with methylation data, significantly improving early-stage UC detection. Fragmentomics combined with methylation markers achieved an AUC of 86.25%, with a sensitivity of 89.3% and a precision of 75.76%, demonstrating substantial improvements in diagnostic accuracy. Conclusions: Urinary cfDNA fragmentomics provides valuable complementary information to traditional molecular markers for detecting urothelial carcinoma. This innovative approach enhances diagnostic precision and shows potential for improving early detection strategies, with promising applications in non-invasive cancer screening and monitoring.
DeepKymoTracker: A tool for accurate construction of cell lineage trees for highly motile cells
Time-lapse microscopy has long been used to record cell lineage trees. Successful construction of a lineage tree requires tracking and preserving the identity of multiple cells across many images. If a single cell is misidentified the identity of all its progeny will be corrupted and inferences about heritability may be incorrect. Successfully avoiding such identity errors is challenging, however, when studying highly-motile cells such as T lymphocytes which readily change shape from one image to the next. To address this problem, we developed DeepKymoTracker, a pipeline for combined tracking and segmentation. Central to DeepKymoTracker is the use of a seed, a marker for each cell which transmits information about cell position and identity between sets of images during tracking, as well as between tracking and segmentation steps. The seed allows a 3D convolutional neural network (CNN) to detect and associate cells across several consecutive images in an integrated way, reducing the risk of a single poor image corrupting cell identity. DeepKymoTracker was trained extensively on synthetic and experimental T lymphocyte images. It was benchmarked against five publicly available, automatic analysis tools and outperformed them in almost all respects. The software is written in pure Python and is freely available. We suggest this tool is particularly suited to the tracking of cells in suspension, whose fast motion makes lineage assembly particularly difficult.
Randomized controlled trial of bromelain and alpha-lipoic acid in breast conservative surgery
Head-to-head comparison of micro-ultrasound, mpMRI, and PSMA PET/CT with a wholemount histopathology as gold standard in the detection and T staging of prostate cancer.
338 Background: Micro-Ultrasound (MicroUS) is a new imaging modality capable of identifying prostate cancer (PCa). Prior evaluation of MicroUS and multiparametric MRI (MRI) have demonstrated comparable accuracy but are limited by relying on biopsy pathology for ground truth. There are no available studies that comprehensively evaluate the diagnostic accuracy and extraprostatic extension (EPE) of MicroUS, MRI, and PSMA PET/CT (PSMA) against wholemount histopathology (WMHP) as the reference. Methods: Patients with PCa who underwent MicroUS and MRI before radical prostatectomy were included. Among the included patients, a subgroup analysis was performed in patients with a PSMA scan. Imaging scans and WMHP findings were translated into involvement on a standardized 36 sector map. Accuracy in determining the PCa, csPCa (GG≥2) and EPE was assessed using receiver-operating-characteristic curve analysis (AUC). Results: The final analysis included 25 patients, 19 of whom underwent PSMA scan. The lesion-level PCa and csPCa detection rates were 55% and 72%, 57% and 75%, 53% and 70% for Micro-US, MRI and PSMA, respectively (Table). For the sector-level analysis, the AUCs of MRI were higher than that of MicroUS and PSMA in identifying PCa, and csPCa (P<0.05). MicroUS and PSMA had comparable sector-level PCa and csPCa AUCs. The AUCs of MRI and PSMA were higher than MicroUS for sector-level EPE (P<0.05). The AUCs for prediction of patient-level EPE were 0.68, 0.69 and 0.54 for MicroUS, MRI and PSMA, respectively (p = NS). Patient level PCa, csPCa, and for specific pathologic features was similar among imaging modalities. Conclusions: MicroUS showed good reliability in identifying csPCa and patient-level EPE. At the patient level, its performance is comparable to that of MRI. MRI performs better at the sector-level. Diagnostic accuracy and EPE staging for MicroUS, MRI, and PSMA PET/CT. N = 25 MicroUS Multiparametric MRI PSMA PET CT P-Value PCa Sector-Level AUC 0.67 (0.64, 0.71) 0.71 (0.68, 0.75) - 0.03 csPCa Sector-Level AUC 0.69 (0.65, 0.72) 0.74 (0.70, 0.77) - 0.01 EPE Patient-Level AUC 0.68 (0.47, 0.88) 0.69 (0.51, 0.87) - 0.93 EPE Sector Level AUC 0.57 (0.47, 0.67) 0.79 (0.65, 0.93) - <0.01 N = 19 PCa Sector-Level AUC 0.66 (0.61, 0.71) 0.62 (0.57, 0.68) 0.62 (0.57, 0.68) 0.03*, <0.01** csPCa Sector-Level AUC 0.67 (0.63, 0.71) 0.71 (0.67, 0.75) 0.64 (0.60, 0.67) 0.06*, <0.01** EPE Patient-Level AUC 0.69 (0.51, 0.87) 0.72 (0.51, 0.94) 0.54 (0.30, 0.78) 0.32*, 0.28** EPE Sector Level AUC 0.54 (0.45, 0.62) 0.78 (0.63, 0.92) 0.73 (0.58, 0.87) 0.01* , 0.50** Pathologic Feature Detection Rates for MicroUS, mpMRI, and PSMA PET CT MicroUS Multiparametric MRI PSMA PET CT P-Value PCa (%) 55.3 57.4 52.8 0.81 csPCa (%) 72.2 75.0 70.4 0.78 Index Lesion (%) 96.0 92.0 84.2 0.26 Cribiform/IDC (%) 94.1 100 83.3 0.08 EPE (%) 44.4 66.7 62.5 0.17 *MicroUS vs. PSMA PET/CT. **mpMRI vs PSMA PET/CT.
Comparison of IO-TKI vs IO-IO combinations in IMDC poor-risk metastatic renal cell carcinoma (mRCC) patients (Meet-URO 33 analysis).
495 Background: Immune-combinations have become the cornerstone of the mRCC treatment landscape, but head-to-head comparisons between the different first-line treatment strategies are lacking and few real-world data are available in this setting. In this context, little evidence is available, especially for IMDC poor-risk patients, who have the worst prognosis and lowest response to standard treatments. Methods: The Meet-URO 33 study is an Italian retrospective/prospective registry of the first-line setting of mRCC patients from January 2021 (Trial registration: CESC IOV 2023-78, PMID: 38914928) with the aim to answer as many clinical questions as possible. This analysis focused on assessing the different performance of IO-TKI and IO-IO combinations in terms of survival and response outcomes and the differential baseline clinical characteristics in the two treatment groups. Results: Among 892 patients enrolled from 40 Italian centres, 772 patients (87%) were evaluable for survival analyses; 160 patients (21%) had IMDC poor risk: 42 (26%) received IO-IO, 105 (66%) IO-TKI and 13 (8%) TKI. Comparing the baseline clinical characteristics of patients included in the two immune-combinations, poor-risk patients receiving IO-IO were older (mean age: 68 vs 64, p=0.03), had more cardiovascular comorbidities (74% vs 56%, p=0.048) and lower frequency of bone metastases (29% vs 57%, p=0.002). After a mFUP of 6.9 months (mo), the mOS of all poor-risk patients was 11.3 months, higher with IO-IO than with IO-TKI [20.6 vs 11 mo, HR 1.65 (0.97-2.82); p=0.067]. After multivariable analysis (age, comorbidities, ECOG, bone metastases) the difference between IO-TKI and IO-IO was not statistically significant [HR 1.37 (0.78-2.40); p=0.27]. The overall mPFS was 6.4 mo, higher with IO-IO compared with IO-TKI [11 vs 5.8 mo, HR 1.70 (1.05-2.75); p=0.031]. After the multivariable analysis, the difference between the two treatment groups lost statistical significance [HR 1.58 (0.95-2.63); p=0.078]. The general ORR was 46%, higher with IO-TKI than with IO-IO [71% vs 29%, OR 0.70 (0.21-1.56); p=0.38]. Conclusions: These preliminary analyses of the ongoing Meet-URO 33 study show no clear survival advantage in using an IO-TKI combinations instead of an IO-IO combination in IMDC poor-risk patients. These results are in line with the well-known smaller benefit of TKI in poor-risk patients (more immunogenic / less angiogenic patterns and results of the COSMIC-313 study). A longer follow-up is needed to examine in depth the different performance of immune-combinations in IMDC poor-risk patients. Clinical trial information: CESC IOV 2023-78 .
Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform.
21 Background: Recent phase III data (n=1360) has shown that starting ADT with tE2 patches is non-inferior in terms of metastasis-free survival (with similar overall survival) to luteinising hormone releasing hormone analogues (LHRHa) for locally advanced (M0) prostate cancer. For both M0 and M1 patients, tE2 has advantages in terms of reported quality of life, bone mineral density, hot flushes and metabolic outcomes compared to LHRHa, with no excess of thromboembolic events. However, there is currently no data on the use of androgen receptor pathway inhibitors (ARPIs) (abiraterone, enzalutamide or apalutamide) with tE2. Methods: STAMPEDE [NCT00268476] is a multi-arm, multi-stage platform trial. This embedded phase 2 randomised study assessed efficacy and toxicity in participants (pts) randomly allocated (1:1) to tE2 patches (releasing 100mcg/24hrs, 3 patches changed twice weekly once testosterone ≤1.7ng/ml) or LHRHa (standard doses) and scheduled to receive ARPIs. Primary outcome measure was the proportion of pts reaching a PSA nadir of ≤0.2ng/ml during the first 6 months. Other PSA parameters, testosterone ≤1.7ng/ml at 12 weeks with tE2, and adverse events within the first 12 months (including hypertension, hot flushes and gynaecomastia) were assessed. Results: Between Oct-2020 and Mar-2023, 79 pts with histologically confirmed M1 prostate cancer (median (IQR) age 69 (65-75), median (IQR) baseline PSA 43.3 (11.5-296.2)) received either LHRHa+ARPI (n=41) or tE2+ARPI (n=38). Baseline characteristics were similar between the 2 groups. The proportion of pts achieving PSA ≤0.2ng/ml was LHRHa+ARPI 25/41 (61%) and tE2+ARPI 23/38 (61%). LHRHa v tE2: PSA90 (93% v 95%) and PSA50 (100% v 100%). 31/34 (91%) men treated with tE2 had testosterone ≤1.7ng/ml at 12 weeks. Hot flushes: LHRHa (grade 1: 32%, grade 2: 20%) v tE2 (grade 1: 24%, grade 2: 5%). Gynaecomastia: LHRHa (grade 1: 10%, grade 2: 0%) v tE2 (grade 1: 35%, grade 2: 8%) and any grade hypertension LHRHa v tE2 17% versus 5%. Conclusions: PSA responses were similar in pts treated with tE2+ARPI or LHRHa+ARPI further supporting the use of tE2 patches for ADT in prostate cancer management. tE2 patches provide patients with ADT choices about expected toxicity profiles, including reduced hot flushes (and subsequent impact on quality of life), and mode of administration. Clinical trial information: NCT00268476 .